Ongoing clinical trials in maintenance or consolidation setting after first line treatment for SCLC
| Clinical trial ID | Phase | Setting | Regimen | Endpoint |
|---|---|---|---|---|
| NCT02046733 (STIMULI) | II | LD-SCLC, after C-RT | Nivolumab plus ipilimumab | OSPFS |
| NCT03043599 | I/II | LD-SCLC, after Cx | Nivolumab plus ipilimumab plus RT | RP2DPFS |
LD-SCLC Limited-stage Disease Small cell lung cancer, C-RT chemo-radiation, OS Overall Survival, PFS Progression Free Survival, Cx Chemotherapy, RT Radiotherapy, RP2D Recommended Phase 2 Dose, ED-SCLC Extensive-stage Disease Small cell lung cancer